Account
News
16.11.2023
ISPOR Europe 2023

We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Are Acute Therapies And Curativ...

We've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...

Read more
Webinar
06.10.2023
Orphan Medicine Market Access in Europe

Webinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...

Read more
Articles
07.09.2023
HUMN legislation – enabler or barrier for advanc...

This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...

Read more
Articles
07.09.2023
Prescription Price Puzzles: The Sky-High Cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
Articles
21.06.2023
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
Insider Insights
05.05.2023
HAS issues favorable reimbursement opinion

This is the first time that HAS is issuing a favorable opinion for the reimbursement of a technology...

Read more
News
30.03.2023
PMA Insights: Week 13 SPECIAL EDITION – Worl...

We summarise the World EPA Congress 2023 including plenary sessions on EU HTA, market archetypes, he...

Read more
Insider Insights
22.03.2023
More clarity given on the proposed changes to comb...

The German government has released information regarding the 20% discounts to combination products e...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.